RegulatoryOfficial
European Commission authorises Gedeon Richter's Inijaq, a new tofacitinib product
🇪🇺 European Commission (Union Register) · Thu 12 Nov 2026
Commission Decision (2026) 8201 of 12 November 2026 grants marketing authorisation to Inijaq (tofacitinib), adding another tofacitinib medicine to the EU market.
The European Commission has granted a marketing authorisation to Inijaq, a tofacitinib-containing medicine from Gedeon Richter Plc. The authorisation was issued through Commission Decision (2026) 8201 of 12 November 2026.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Official source: European Commission (Union Register) ↗
Article written by VigiEye from the official source (European Commission (Union Register)). AI-assisted; check the source before acting.
More Regulatory
All →
Galectin files belapectin Phase 3 protocol with FDA as chairman converts $105.8M debt
🇺🇸 Galectin Therapeutics Inc (GALT) · Mon 16 Nov 2026
Apnimed's sleep apnoea drug AD109 awaits FDA decision with 28 February 2027 goal date
🇺🇸 Apnimed, Inc. (APMD) · Mon 16 Nov 2026
FDA sets 25 March 2027 goal date for Unicycive's resubmitted oxylanthanum carbonate application
🇺🇸 Unicycive Therapeutics, Inc. (UNCY) · Mon 16 Nov 2026
FDA grants orphan drug designation to Noema's basimglurant for trigeminal neuralgia
Noema Pharma AG · Mon 16 Nov 2026
FDA issues complete response letter for Summit's ivonescimab in EGFR-mutant NSCLC
🇺🇸 Summit Therapeutics Inc. (SMMT) · Mon 16 Nov 2026
Invivyd Q3 Pemgarda revenue reaches $15.4M as VYD2311 data timing shifts after FDA talks
🇺🇸 Invivyd, Inc. (IVVD) · Mon 16 Nov 2026